Combination immuno-oncology therapy with immune checkpoint blockers targeting PD-L1, PD-1 or CTLA4 and epigenetic drugs targeting MYC and immune evasion for precision medicine.

ABSTRACT:

SUBMITTER: Katoh M 

PROVIDER: S-EPMC5906241 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature